From the Journals

KRAS-targeted T-cell therapy derails metastatic cancer


 

FROM THE NEW ENGLAND JOURNAL OF MEDICINE

Adoptive transfer of cytotoxic T cells targeting a specific KRAS mutation (KRAS G12D) expressed by a metastatic colorectal cancer induced the regression of all seven lung metastases in a single patient, investigators report in the New England Journal of Medicine.

They described the case of a 50-year-old woman participating in an ongoing phase II clinical trial assessing adoptive transfer of tumor-infiltrating lymphocytes targeting personalized cancer neoepitopes (individualized T-cell therapy). This patient was the only participant to date in whom the treatment induced tumor regression.

A total of 3 of her 10 lung metastases were resected to identify mutations expressed by the tumors, and these were found to express mutant KRAS G12D and HLA-C*08:02. The lymphocyte cultures that reacted most strongly against these antigens were expanded and made into a single infusion, which was administered after the patient had undergone nonmyeloablative conditioning using cyclophosphamide and fludarabine. The patient then received five doses of interleukin-2, which produced the only adverse effect of the entire regimen, fatigue.

At 40-day follow-up, all seven remaining lung metastases showed marked regression. One lesion showed progression at 9-month follow-up and was resected, and the patient has remained cancer free for the subsequent 4 months (N Engl J Med. 2016 Dec 8. doi:10.1056/NEJMoa1609279).

Laboratory analysis of the one metastasis that progressed showed that it had mutated further, losing heterozygosity of the copy of chromosome 6 that encoded HLA-C*08:02. “The presence of this molecule is required for direct tumor recognition by the transferred KRAS G12D-specific T cells. ... [Such a loss] has been observed in human cancers and may represent a hurdle that needs to be overcome to enhance immunotherapeutic efficacy in some patients,” Dr. Tran and his associates wrote.

“In such cases, targeting antigens that are presented by the remaining HLA class I alleles or exploiting the CD4+ T-cell response or the innate immune system against cancer may be necessary to induce a durable clinical response,” they added.

Recommended Reading

VIDEO: Y90 radioembolization beat chemoembolization in liver cancer
MDedge Hematology and Oncology
New scale bests Milan criteria in predicting posttransplant HCC recurrence
MDedge Hematology and Oncology
Study eyed zinc for slowing progression of chronic liver disease
MDedge Hematology and Oncology
SNP predicts liver cancer in hepatitis C patients regardless of SVR
MDedge Hematology and Oncology
Emergent colon cancer resection does not negatively affect patient outcomes
MDedge Hematology and Oncology
Tumor boards linked to improved survival in hepatocellular carcinoma
MDedge Hematology and Oncology
Impact of a literacy-sensitive intervention on CRC screening knowledge, attitudes, and intention to screen
MDedge Hematology and Oncology
Increased death rate with platelets for aspirin/clopidogrel GI bleed
MDedge Hematology and Oncology
HCV patients with early-stage hepatocellular carcinoma can achieve SVR
MDedge Hematology and Oncology
Genetics dictate interferon-alfa diarrhea risk
MDedge Hematology and Oncology